title: CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Theurich
authors.forename: Kerstin
authors.initials: K
authors.lastname: Wennhold
authors.forename: Inga
authors.initials: I
authors.lastname: Wedemeyer
authors.forename: Achim
authors.initials: A
authors.lastname: Rothe
authors.forename: Kai
authors.initials: K
authors.lastname: Hübel
authors.forename: Alexander
authors.initials: A
authors.lastname: Shimabukuro-Vornhagen
authors.forename: Udo
authors.initials: U
authors.lastname: Holtick
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.forename: Christof
authors.initials: C
authors.lastname: Scheid
authors.forename: Michael
authors.initials: M
authors.lastname: von Bergwelt-Baildon
mesh_terms: D000368:Aged; D000079963:Brentuximab Vedotin; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007111:Immunity, Cellular; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors*; D017710:Lymphocyte Transfusion; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D012074:Remission Induction; D014184:Transplantation, Homologous
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin